

Healthcare Innovations Trust

Series 2

A 2 Year Unit Investment Trust

Healthcare Industry

Scientific innovations are driving opportunities in the healthcare industry. The increasing understanding of the disease mechanism, genomics enabling precision medicine, and improved therapeutics have been significant catalysts to the spending and investments in healthcare.

In addition to innovation, demographics are driving overall demand. Consider the following:

- Increase in life expectancies
- Aging population (more than 1.4 billion of population will be over the age of 60 by 2030)
- Half of all lifetime care expenditures occur from the age of 65 and upwards
- Increase in rate of chronic illnesses globally

Innovation and demographics present opportunities for investors in the healthcare industry.

Investment Objective

The trust seeks total return potential through capital appreciation. There is no guarantee that the investment objectives of the trust will be achieved.

Investment Strategy

The trust seeks to pursue its objective by investing in a portfolio consisting of equity securities comprising the Poliwogg Healthcare Innovation Index (PHIX).



About the Healthcare Innovation Index

Poliwogg's focus is on innovation and biotechnology (biotech), not big pharmaceutical companies. Typically, pharmaceutical drugs target symptoms of diseases. Conversely, biotech drugs target the underlying diseases themselves. Big pharma's preferred approach to biotech is through acquisition. This particular index is designed to isolate biotech companies that are potential takeover targets. Index inclusion criteria includes, but is not limited to:

Biotech companies with at least one drug in phase II or III clinical trial which meet one of the following criteria:

- Expected catalyst event date within 24 months
- Drug designation of breakthrough, fast track, or orphan

About the Research Provider

Poliwogg is a financial services company whose mission is to create innovative financial products that give both institutional and retail investors the widest possible opportunity to invest in the most dynamic sectors and subsectors of the life sciences – medical innovations and breakthroughs.

Poliwogg's management team has extensive experience in finance and investment, healthcare, foundations, and government. It combines that expertise with a passion for increasing and broadening investment in healthcare.

Description of Portfolio

INCEPTION DATE:	November 2, 2016
TERMINATION DATE:	November 1, 2018
INITIAL OFFER PRICE:	\$10.00
MINIMUM INVESTMENT:	100 units (may vary by selling firm)
NUMBER OF ISSUES:	29
DISTRIBUTIONS: ¹	MONTHLY (if any)
EST. NET ANNUAL 1ST YR DISTRIBUTIONS: ²	\$0.0000 (per unit)
CUSIP (CASH):	83185R 103
CUSIP (REINVESTMENT):	83185R 111
FEE-BASED CUSIP (CASH):	83185R 129
FEE-BASED CUSIP (REINVESTMENT):	83185R 137
TICKER:	SMHCBX

¹Distributions, if any, will be made commencing on December 25, 2016. The estimated net annual distribution is expected to decline over time because a portion of the securities included in the portfolio will be sold to pay for organization costs, creation and development fee and deferred sales charge. Distributions will fluctuate as a result of unitholder redemptions in addition to securities being sold within the portfolio. Distributions are also subject to the ability of issuers to make dividend payments in the future.

²Estimated Net Annual First Year Distribution per unit is computed by dividing the estimated annual income of the underlying securities less the expense per unit by the number of units outstanding. The estimated net annual distributions for subsequent years are expected to be less than estimated distributions for the first year because a portion of the securities included in the trust portfolio will be sold during the first year to pay for organization costs, the creation and development fee and the deferred sales charge. The actual net annual distributions will vary with changes in the trust's fees and expenses and income of the underlying securities.

Investors should consider the trust's investment objective, risks, charges and expenses carefully before investing. The prospectus contains this and other information relevant to an investment in the trust. Please read the prospectus carefully before you invest. If a prospectus did not accompany this literature, please contact SmartTrust at (888) 505-2872 to obtain a free prospectus.

Hennion & Walsh is a member of FINRA/SIPC.

2001 Route 46, Waterview Plaza, Parsippany, NJ 07054 (888) 505-2872 www.smarttrustuit.com

NOT FDIC INSURED • NOT BANK GUARANTEED • MAY LOSE VALUE

Sales Charges⁴ (based on a \$10 public offering price)

Standard Accounts

Transactional Sales Charge:	Initial	1.00%
	Deferred	2.45%
Creation & Development Fee ⁵ :		0.50%
Maximum Sales Charge:		3.95%

The deferred sales charge is a charge of \$0.245 per unit and will be deducted in three monthly installments commencing on May 20, 2017. The initial and deferred sales fees do not apply to fee-based accounts. Please see the prospectus for sales charge details.

Fee/Wrap Accounts

Creation & Development Fee ⁵ :	\$0.05
Maximum Sales Charge:	\$0.05

⁴Percentages are based on a \$10.00 per unit offering price. For unit prices other than \$10.00, percentages of initial sales charge, creation and development fee, and deferred sales charges will vary. Early redemption will still cause payment of the deferred sales charge. The table above shows the initial offering period sales charges only.

⁵The creation and development fee is a charge of \$.050 per unit collected at the end of the initial offering period. If the price you pay exceeds \$10 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than \$10 per unit, the creation and development fee will exceed 0.50%. In addition to the sales charges listed, UITs are subject to annual operating expenses and organization costs.

Volume Discounts

PURCHASE AMOUNT ³	SALES CHARGE
Less than \$50,000	3.95%
\$50,000 but less than \$100,000	3.70%
\$100,000 but less than \$250,000	3.45%
\$250,000 but less than \$500,000	3.10%
\$500,000 but less than \$1,000,000	2.95%
\$1,000,000 or greater	2.45%

³The volume discount is also applied on a unit basis utilizing a breakpoint equivalent in the above table of one unit per \$10. Please see the trust prospectus for full details. These discounts are only offered during the initial offering period.

Portfolio Holdings as of November 2, 2016:

Equity Securities — 100.00%	
Health Care — 100.00%	
ACAD	ACADIA Pharmaceuticals Inc.
XLRN	Acceleron Pharma Inc.
ACOR	Acorda Therapeutics, Inc.
AGIO	Agios Pharmaceuticals, Inc.
ALDR	Alder BioPharmaceuticals, Inc.
ALXN	Alexion Pharmaceuticals, Inc.
ALKS	Alkermes plc
ALNY	Alnylam Pharmaceuticals, Inc.
ARIA	ARIAD Pharmaceuticals, Inc.
AXON	Axovant Sciences Ltd.
BMRN	BioMarin Pharmaceutical Inc.
CEMP	Cempra, Inc.
DBVT	DBV Technologies S.A.
FGEN	FibroGen, Inc.
FPRX	Five Prime Therapeutics, Inc.
HZNP	Horizon Pharma plc
JAZZ	Jazz Pharmaceuticals plc
KITE	Kite Pharma, Inc.
LXRX	Lexicon Pharmaceuticals, Inc.
MDCO	The Medicines Company
NBIX	Neurocrine Biosciences, Inc.
PCRX	Pacira Pharmaceuticals, Inc.
PTLA	Portola Pharmaceuticals, Inc.
PRTA	Prothena Corporation plc
PBYI	Puma Biotechnology, Inc.
SRPT	Sarepta Therapeutics, Inc.
SGEN	Seattle Genetics, Inc.
RARE	Ultragenyx Pharmaceutical Inc.
VRTX	Vertex Pharmaceuticals Incorporated

Risk Considerations

Unitholders can lose money by investing in this trust. An investment in units of the trust should be made with an understanding of the risks related to the trust, such as the following:

- Security prices will fluctuate. The value of your investment may fall over time.
- The financial condition of an issuer may worsen or its credit ratings may drop, resulting in a reduction in the value of your units. This may occur at any point in time, including during the initial offering period.
- The issuer of a security may be unwilling or unable to declare dividends in the future or may reduce the level of dividends declared. This may reduce the level of distributions the trust pays which could reduce your income and cause the value of your units to fall.
- The trust invests in securities from the Index selected prior to the date of the trust's formation. The securities in the trust's portfolio will not change if the Index components, or their weightings within the Index, change. The performance of the trust may not correspond with the Index for this reason and because the trust incurs a sales charge and expenses.
- The trust is considered to be concentrated in securities issued by companies in the health care sector. Negative developments in this sector will affect the value of your investment more than would be the case in a more diversified investment. General risks of companies in the health care sector include extensive competition, generic drug sales, the loss of patent protection, product liability litigation, increased government regulation, and challenges in obtaining regulatory approval for drugs and therapies.
- The trust may invest in stocks of small and mid-size companies. These stocks are often more volatile and have lower trading volumes than stocks of larger companies. Small and mid-size companies may have limited products or financial resources, management inexperience and less publicly available information.
- The trust is not actively managed. Except in limited circumstances, the trust will hold, and continue to buy, shares of the same securities even if their market value declines.
- The sponsor may offer successive trusts with similar portfolios thereby allowing the investor to pursue the same strategy over a number of years. Investors should consider their ability to pursue investing in successive trusts, if available. There may be tax consequences associated with investing in the trust and rolling over an investment from one trust to the next.